Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Lately, I’ve been avoiding phone calls and texting people more than I used to. I might prefer to pick up a phone, but then I think calling someone will interrupt their day and be an unwelcome ...
Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...
This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...
Similar to the iPhone, the Google Phone and Contacts apps are introducing customizable “calling cards” that some beta users are beginning to see. Instead of just seeing a person’s profile picture at ...
RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Forbes contributors publish independent expert analyses and insights. The author of many tech books, Michael Ashley covers AI and Big Data. If you’re anything like me, your phone rings all day with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback